Introduction
been applied in the effort to quantify the SCS effect on blood flow. Transcutaneous oxygen tension (TcpO 2 ) Spinal cord stimulation (SCS) seems an established measured by Clark's electrode seems to be a reliable noninvasive method of tissue perfusion, useful for assessing treatment for patients with peripheral arterial occlusive disease (PAOD). [1] [2] [3] [4] [5] Initially, the method was used to PAOD. [11] [12] [13] [14] [15] [16] [17] [18] TcpO 2 measurement has already been used as a predictive parameter to evaluate ulcer-healing in endmanage patients with chronic intractable pain, 7 or to improve motor function in patients with partial spinal stage vascular patients treated with SCS. 11 The efficacy of SCS in diabetic patients with severe cord lesions. 7 SCS has also been used successfully to manage diabetic patients with advanced peripheral lower-limb ischaemia and peripheral neuropathy has not, to our knowledge, been investigated before. The neuropathic pain. 8 Peripheral neuropathy is a common long-term complication of diabetes 8 and about 7.5% of purpose of this prospective study was to investigate whether the TcpO 2 measurements before and during the diabetic population have painful neuropathic symptoms, mainly affecting the lower limb. 9 the SCS treatment in diabetic patients could be used to predict therapy success and to select patients for SCS has beneficial effects on peripheral blood flow of the lower limbs, with improvement of walking ability, permanent device implantation. healing of trophic lesions, increase in cutaneous temperature and reduction or disappearance of skin discoloration. 10 Non (1) Heart-rate response to Valsalva manoeuvre which included the assessment of neuropathic symp-(patient position: sitting); toms and deficit scores. Local exclusion criteria included (2) Heart-rate (R-R intervaal) variation during deep unmeasurable ankle pressure due to non-compressible breathing (sitting); calcified arteries, deep ulceration, osteomyelitis, wet gan-(3) Immediate heart-rate response to standing (lying grenous lesions >3 cm 2 , peripheral neuropathy due to 5-10 min to standing). other causes (e.g. alcohol) and inability to perform se-(B) Tests reflecting cardiac sympathetic damage; lective angiography. Systemic exclusions included a life-(4) Blood-pressure response to standing (lying expectancy of less than 18 months due to concomitant 5-10 min to standing) and diseases, significant heart failure, severe pulmonary or (5) Blood-pressure response to sustained handgrip renal insufficiency, unstable angina, a non-cooperative (sitting). patient and spinal disease.
The duration of vascular history ranged from 6 Orthostatic hypotension was defined as a drop of months to more than 6 years. Prior to implantation, at least 20 mmHg in systolic or diastolic blood pressure all patients had received conservative treatment (pen-upon standing. All the subjects were carefully intoxiphylline, antiplatelet agents, defibrotide, bu-structed before test start. The neuropathic score, ranflomedil), including management of risk factors, pain ging from 0 to 5, was calculated assigning zero for therapy (tricylic antidepressants, non-steroid anti-in-normal values, one point for every abnormal test and flammatories, or dihydrocodeine plus paracetamol) half a point for borderline value test. Early neuropathy and surgical foot care.
was defined as an abnormality of one of the three tests Intra-arterial subtraction or intraoperative selective of parasympathetic function, and definite neuropathy arteriograms were obtained from all patients and corresponded to two or more abnormal parashowed occluded distal vessels, unsuitable for a bypass sympathetic tests with or without abnormal symprocedure or angioplasty. If only ankle or foot arteries pathetic tests. The 28 patients with diabetic neuropathy were available to bypass, but autogenous vein un-had one or more complications of diabetes mellitus available, the patient was regarded as non-re-such as retinopathy, peripheral neuropathy and nephconstructible. Failed bypass-procedures in the ropathy. In 15 patients early autonomic neuropathy involved leg were noted in 27 patients, while, in 24, (1-1.5 points in five patients and 2 in 10 patients) and in exploration of tibial or/and popliteal arteries dem-13 patients definite autonomic neuropathy combined onstrated advanced diabetic atherosclerotic disease. with sympathetic damage (from 2.5 to 3.5) were found. Five patients had a contralateral amputation. Twenty diabetic patients Fontaine's stage III (7 with neuropathy) with ischaemic rest pain of at least two months' duration, 20 diabetic patients stage IV (9 with neurTranscutaneous oxygen tension (TcpO 2 ) protocol opathy) with ulcers <3 cm 2 and 20 (12 with neuropathy) with trophic lesions >3 cm 2 with dry gangrene of one TcpO 2 (in mmHg) at the dorsum of the foot was measor two toes, were included in the present study and ured using the Microspan Combo TcpO 2 /pCO 2 moniwere treated with SCS. All patients gave informed toring system (Biochem International Inc., WI, U.S.A.), consent to participate in the study.
to evaluate the reduction in skin circulation. The severity of PAOD was accurately determined using the TcpO 2 , which is known to correlate with the clinical Assessment of autonomic neuropathy stage of the disease. [12] [13] [14] [15] [16] [17] [18] The TcpO 2 was measured by Clark's electrode and seems to be a reliable non-invasive Autonomic neuropathy was evaluated using the cardiovascular autonomic neuropathy tests according index of tissue perfusion, useful for assessing peripheral arterial occlusive disease. [12] [13] [14] [15] [16] The electrode, attached to to Ewing and Clarke.
19 These tests give a practical guide that we consider reliable, reproducible, simple the dorsum of the foot, was warmed to 44°C, causing maximum vasodilatation of the underlying skin cirand non-invasive. The total time required was about 20 min and the equipment needed includes a sphygmo-culation and was allowed to stabilise on the skin for 15 minutes before the measurement was taken. 13,15 TcpO 2 manometer, an electrocardiograph, an aneroid manometer, a handgrip dynamometer, plus couch and measurements were performed with the transducer placed at the same site, marking the skin with per-feeling of warmth in the painful area indicated optimal stimulation. The setting parameters were pulse ampmanent ink, at the dorsum of the foot before, 2 and 4 weeks after SCS device implantation, with the patient litude between 1.0 and 5.0 V, frequency between 40 and 120 pps and pulse width from 150 to 450 ms. in a supine position in a controlled room temperature (25°C), after a rest lasting at least 30 min.
Stimulation was continuous, lasting 24 h a day to obtain the maximum information on the clinical outSystolic arterial ankle and toe pressures (in mmHg) were measured using bi-directional Doppler ultra-come. During follow-up the parameters of stimulation can be reset with the help of a portable computer, sonography in the posterior tibial and pedal arteries, respectively and then in the toe artery. The ABPI was according to the patient clinical status. determined by dividing systolic ankle pressure by systolic brachial artery pressure.
Statistical analysis Clinical improvement and pain relief evaluation
The TcpO 2 data were calculated as mean values and standard deviations. Paired t-tests with appropriate Analysis of patient pain relief and clinical improvement correction to reduce type-I errors and Fisher's exact were evaluated before implantation, then 2 and 4 weeks test were applied. A p value of <0.05 was considered after. Thereafter patients were seen every three months statistically significant. for a minimum of 18 months. The presence of comfortable paraesthesia instead of pain, feelings of warmth, reduction in size of the trophic lesions, imResults provement of the pain-free walking interval under standard conditions (treadmill), an uninterrupted All patients experienced some pain relief during the test sleep, were evaluated. The pain relief and the method stimulation period. Among the 20 patients with rest success were based on the intake of analgesic drugs pain, limb salvage for more than 18 months and pain (minor or narcotics) and patients' self-evaluation using relief >75% were obtained in 15. Partial success was a visual analogue scale (VAS). Success was defined as achieved in four patients (pain relief >50% and limb pain relief of >75% and limb salvage for at least 18 salvage for at least 6 months). In one patient SCS failed months with only minor amputation (toe). Partial sucto salvage the limb and the patient underwent major cess was defined as limb salvage for at least 6 months amputation within 6 months (Table 1) . Among the 20 associated with pain relief evaluated between 50% and patients with trophic lesions <3 cm 2 , limb salvage for 70%. Failure was defined as pain relief evaluated as more than 18 months and pain relief >75% were ob-<50% and limb loss within the first 6 months. tained in 12 patients. Four patients initially had amelioration of their ischaemic pain >50% but it recurred after 6-18 months requiring additional analgesic therImplantation technique apy. Severe ischaemic pain recurred in four patients within the first 6 months after implantation requiring A quadripolar electrode (Pisces-Quad 3487A, Medtronic, Minneapolis, MN, U.S.A.) was placed in the major amputation (Table 1) . Among the 20 patients with trophic lesions >3 cm 2 (dry gangrene), limb salvage for epidural space by percutaneous lumbar puncture between L2 and L3 or L3 and L4. The electrode was more than 18 months and pain relief >75% were obtained in eight patients, while in four patients partial positioned in the midline in most cases, under fluoroscopic guidance up to level T10-11. Connecting a success with pain relief >50% and limb salvage for at least 6 months (mean 9 months range 6-12) was portable stimulator to the electrode allowed intraoperative test stimulation producing comfortable par-achieved. After this period the ischaemic pain recurred and major amputation was unavoidable. The other aesthesias in the painful foot or limb. The clinical effects were tested during a 2-week trial period and eight patients initially achieved minor pain relief <50% but within 2 months additional analgesic medication in the cases where the patient had a significant pain relief, an implantable pulse generator (Itrel II IPG, was necessary. Within 6 months all these patients underwent major amputation (Table 1) . Medtronic Inc. Minneapolis, U.S.A.) was placed in an abdominal subcutaneous pocket. Various settings of TcpO 2 foot values, within the first 2 weeks of the test period, increased from 21.4 s.d. 5.7 mmHg to 31.5 the active quadripolar extremities of the electrode were studied to evaluate the most appropriate combination s.d. 5.4 mmHg (p=0.030) in the patients with rest pain and limb salvage. In the patients with trophic lesions for pain relief. The presence of paraesthesia and a The pain varies within the first 2 weeks after temporary implantation, while a further, but minimal, increase of TcpO 2 after from mild paraesthesia in a few toes to severe unremitting pain in both legs. 9, 22 Night-time exacerbation 4 weeks was revealed in the diabetic patients with limb salvage, compared to the values obtained before of the pain plus contact hypersensitivity to bedclothes results in loss of sleep. 9 The cause of chronic sensorytreatment. Changes of TcpO 2 in all diabetic amputees, where SCS failed to control the ischaemic pain and to motor diabetic neuropathy or indeed neuropathic pain is not known although metabolic and microvascular save the limb, were not significant either after 2 or 4 weeks from the device implantation (Table 3) . No systems may be involved. 23, 24 Whilst the search for potential therapeutic agents to halt or reverse the significant changes were observed in the ABPI or toepressure values before permanent implantation (test neuropathic process continues, 24 current treatment is largely aimed at pain relief. Some authors have demperiod) and during the follow-up.
The patients with long-term SCS success had an onstrated that, in patients with PAOD, SCS recruits small capillaries not ordinarily perfused, enhancing impressive clinical course, with comfortable paraesthesia instead of pain, feelings of warmth, improved skin blood flow, improvements that may explain the beneficial clinical effects experienced by these pain-free walking interval under standard conditions (treadmill), reduction in size of the trophic lesions, patients. 12, 26 However, their data and the use of SCS in the treatment of POAD were recently criticised, and undisturbed sleep without requiring analgesics. because the indications for SCS implantation have not with severe PAOD is over 80%, 13, 15 while authors report a positive predictive value of 77% in the detection of been defined. In critical limb ischaemia, the aim of the SCS should be not only the effective analgesia (which ischaemia, when a cut-off value of 30 mmHg was applied as in our series of patients. 18 The TcpO 2 changes nowadays might be obtained by other less expensive techniques), but also to obtain limb salvage.
related to an increase in skin perfusion, are not a result of improved arterial inflow. 1, 35 SCS has no effect on This study investigated for the first time whether in patients with PAOD and diabetes, the severity of the macrocirculation, 31,32 as demonstrated by the absence of ABPI modifications after stimulation. The feeling of autonomic neuropathy should be assessed before a decision for permanent implantation is taken. Applying warmth and paraesthesia caused by SCS was probably related to the increased TcpO 2 due to amelioration of the simple tests allow clinicians to give some diagnostic precision to the autonomic abnormalities presented in the microcirculation.
In diabetic patients with definite neuropathy the 20-40% of the diabetic population. 27, 28 The relief of ischaemic pain with SCS is probably secondary to the posi-vasomotor tone is already affected. 23, 24, 27, 28 Indeed, in our study these PAOD patients achieved minimal tive effects on microcirculation rather than vice versa. Pain relief may also result in attenuation of sympathetic TcpO 2 changes before and after SCS treatment, despite the relief of the neuropathic pain, which was always activity with vasodilatation, leading to further pain relief. The inhibitory effects of SCS on the transmission of obtained. The diabetic patients with neuropathy generally had a worse course after SCS treatment that was nociceptive impulses may be exerted segmentally 29 in the spinal cord and/or at a supraspinal level. 29 Clinical inversely related to the stage of neuropathy. During the test stimulation all implanted patients noted imobservations indicate that the mechanisms involved in the stimulation-induced relief of ischaemic pain are dif-mediate significant pain relief, while only those with limb salvage achieved significant increase of TcpO 2 ferent from those related to relif of other types of pain. 30 Indeed, nociceptive pain is more resistant to SCS and value following stimulation. It is our opinion that PAOD diabetic patients with additional autonomic significant pain relief is almost never obtained before a couple of days, while neuropathic pain of peripheral neuropathy, without significant increase of TcpO 2 after 2 weeks of the testing period, should be excluded from origin responds well and directly to SCS. 31, 32 Both components, nociceptive as well as neuropathic, are present permanent device implantation for reasons of lack of long-term success and cost effectiveness. in ischaemic pain. Several authors have postulated that the principal factor in the relief of ischaemic pain is the All diabetic patients who benefited from SCS had a significant increase of TcpO 2 within the first 2 weeks inhibition of the pain signal per se, leading to a decrease in sympathetic activity and improved skin micro-of the temporary implantation, suggesting that this time is appropriate as testing period. The success of circulation. [31] [32] [33] Another hypothesis is that stimulation depresses autonomic sympathetic activity and the therapy and limb salvage depends on the obtained differences of TcpO 2 values before and after imaffects 30,34 vasomotor tone by improving cutaneous circulation in ischaemic limb and could be assessed by the plantation rather than the stage of the disease. Indeed, patients with partial success or failure of the method TcpO 2 measurement. [12] [13] [14] [15] [16] [17] [18] Assessment of TcpO 2 measurement, a non-invasive even with high initial value of TcpO 2 but with minimal change after implantation, whatever the stage of the method, is reliable and suitable for evaluation of skin circulation and has been chosen to evaluate micro-disease, had amputation within 6 months after SCS therapy. The sympathetic activity in these cases is circulatory changes induced by SCS in many studies. [12] [13] [14] [15] [16] The accuracy of the method in selecting patients probably depressed and the vasomotor tone and the 
